Current Antiviral Agents Against Human Adenoviruses Associated with Respiratory Infections

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2024 Sep 13

PMID 39268358

Authors

Lexi Li

Zhengde Xie

Lili Xu

Affiliations

Soon will be listed here.

Abstract

Human adenoviruses (HAdVs) are important pathogens responsible for respiratory infections. In children and immunocompromised patients, respiratory infections can cause considerable morbidity and mortality. Currently, there are no approved effective and safe antiviral therapeutics for the clinical treatment of HAdV infections, even those that have undergone preclinical/clinical trials. However, many compounds and molecules with anti-HAdV activity have been explored, and some candidates are undergoing clinical development. Here, we reviewed the reported and efficacies, as well as the therapeutic potential of these antiviral compounds, providing an overview and a summary of the current status of anti-HAdV drug development.

References

Marrugal-Lorenzo J, Serna-Gallego A, Berastegui-Cabrera J, Pachon J, Sanchez-Cespedes J . Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections. Sci Rep. 2019; 9(1):17. PMC: 6327057. DOI: 10.1038/s41598-018-37290-3. View

Marrugal-Lorenzo J, Serna-Gallego A, Gonzalez-Gonzalez L, Bunuales M, Poutou J, Pachon J . Inhibition of adenovirus infection by mifepristone. Antiviral Res. 2018; 159:77-83. DOI: 10.1016/j.antiviral.2018.09.011. View

Holcakova J, Tomasec P, Bugert J, Wang E, Wilkinson G, Hrstka R . The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. Antivir Chem Chemother. 2010; 20(3):133-42. PMC: 2948526. DOI: 10.3851/IMP1460. View

Aguilar-Guisado M, Marrugal-Lorenzo J, Berastegui-Cabrera J, Merino L, Pachon J, Sanchez-Cespedes J . In vitro co-infection by cytomegalovirus improves the antiviral activity of ganciclovir against human adenovirus. Int J Antimicrob Agents. 2020; 56(2):106046. DOI: 10.1016/j.ijantimicag.2020.106046. View

Mentel R, Wegner U . Evaluation of the efficacy of 2',3'-dideoxycytidine against adenovirus infection in a mouse pneumonia model. Antiviral Res. 2000; 47(2):79-87. DOI: 10.1016/s0166-3542(00)00088-7. View

Hong J, Lee H, Piedra P, Choi E, Park K, Koh Y . Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis. Clin Infect Dis. 2001; 32(10):1423-9. DOI: 10.1086/320146. View

Liu C, Wang Y, Wu C, Pei R, Song J, Chen S . Dioscin's antiviral effect in vitro. Virus Res. 2012; 172(1-2):9-14. DOI: 10.1016/j.virusres.2012.12.001. View

Nemerow G, Stewart P, Reddy V . Structure of human adenovirus. Curr Opin Virol. 2012; 2(2):115-21. PMC: 3322384. DOI: 10.1016/j.coviro.2011.12.008. View

Prasad V, Suomalainen M, Hemmi S, Greber U . Cell Cycle-Dependent Kinase Cdk9 Is a Postexposure Drug Target against Human Adenoviruses. ACS Infect Dis. 2017; 3(6):398-405. DOI: 10.1021/acsinfecdis.7b00009. View

10.

Hutterer C, Eickhoff J, Milbradt J, Korn K, Zeittrager I, Bahsi H . A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations. Antimicrob Agents Chemother. 2015; 59(4):2062-71. PMC: 4356785. DOI: 10.1128/AAC.04534-14. View

11.

Lankester A, Heemskerk B, Claas E, Schilham M, Beersma M, Bredius R . Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin Infect Dis. 2004; 38(11):1521-5. DOI: 10.1086/420817. View

12.

Duan Y, Xu B, Li C, Bao Y, An S, Zhou Y . Molecular Characteristics of Human Adenovirus Type 3 Circulating in Parts of China During 2014-2018. Front Microbiol. 2021; 12:688661. PMC: 8276179. DOI: 10.3389/fmicb.2021.688661. View

13.

Hromas R, Clark C, Blanke C, Tricot G, Cornetta K, Hedderman A . Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994; 14(4):663-4. View

14.

Mazzotta S, Marrugal-Lorenzo J, Vega-Holm M, Serna-Gallego A, Alvarez-Vidal J, Berastegui-Cabrera J . Optimization of piperazine-derived ureas privileged structures for effective antiadenovirus agents. Eur J Med Chem. 2019; 185:111840. DOI: 10.1016/j.ejmech.2019.111840. View

15.

Hartley C, Hartley M, Pardoe I, Knight A . Ionic Contra-Viral Therapy (ICVT); a new approach to the treatment of DNA virus infections. Arch Virol. 2006; 151(12):2495-501. DOI: 10.1007/s00705-006-0824-x. View

16.

Abe S, Miyamura K, Oba T, Terakura S, Kasai M, Kitaori K . Oral ribavirin for severe adenovirus infection after allogeneic marrow transplantation. Bone Marrow Transplant. 2003; 32(11):1107-8. DOI: 10.1038/sj.bmt.1704276. View

17.

Hartline C, Gustin K, Wan W, Ciesla S, Beadle J, Hostetler K . Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis. 2005; 191(3):396-9. DOI: 10.1086/426831. View

18.

Romanutti C, Bruttomesso A, Castilla V, Galagovsky L, Wachsman M . Anti-adenovirus activity of epiandrosterone and dehydroepiandrosterone derivatives. Chemotherapy. 2010; 56(2):158-65. DOI: 10.1159/000313530. View

19.

Hoffmann H, Kunz A, Simon V, Palese P, Shaw M . Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A. 2011; 108(14):5777-82. PMC: 3078400. DOI: 10.1073/pnas.1101143108. View

20.

Wold W, Tollefson A, Ying B, Spencer J, Toth K . Drug development against human adenoviruses and its advancement by Syrian hamster models. FEMS Microbiol Rev. 2019; 43(4):380-388. DOI: 10.1093/femsre/fuz008. View